about
Sumatriptan (oral route of administration) for acute migraine attacks in adultsOral sumatriptan for acute migraineOral sumatriptan for acute migraineOn serotonin and migraine: a clinical and pharmacological reviewUse and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data.How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.Intractable eye pain: indication for triptans.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine.From serotonin receptor classification to the antimigraine drug sumatriptan.Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruptionEffects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat.Emerging targets in migraine.Comparative tolerability of treatments for acute migraine: A network meta-analysis.Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan.Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat.Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice.Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being.Therapeutic advances in migraine.Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials.Genetic epidemiology of migraine and cluster headache.Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial.Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.Effects of sumatriptan on cerebral blood flow under normo- and hypercapnia in rats.Placebo adverse events in headache trials: headache as an adverse event of placebo.When to stress over triptans: a Markov analysis of cardiovascular risk in migraine treatment.Effective headache management. Strategies to help patients gain control over pain.Triptans in the treatment of migraine: drug selection by means of the SOJA method.Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine?Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.
P2860
Q24203707-BA1DFA80-459B-4B6B-9F76-F7E5F56CFB7CQ24203742-78F70797-429F-46FF-A5BA-88E209250C06Q24248078-E9AD6F4E-02FF-4962-8747-22FE2ED8068CQ28263827-93E41E1C-2ABA-4437-9ACF-9BF9D3DB3549Q30584718-0721577B-80C4-404D-ACED-3266686B7E59Q30692301-7550E3D9-E401-461F-8F25-4882CC0C847AQ31789269-C1711A2B-10F7-47FA-8D11-67E646DD4806Q32124850-4D74AE35-81FF-43CB-BEFE-FB7BC989F8B1Q34154647-F33B4759-9306-46EC-9016-4CD8B9202B58Q35229339-D8D5A450-9A66-488F-8264-3E37540B751FQ35233143-65726906-BFA3-440D-9A56-07B75C7B1EC6Q36329540-B535317E-AFD7-4918-B810-DD3B9136D05AQ36330113-F41E5C62-E6D4-49E3-B90E-6016D2FCE071Q38169593-2F86A187-4579-4AFD-865C-6A0CE8F3289EQ38927015-EAB37101-F5FF-4794-9863-B48FB79CBA4CQ39427714-519E7D2F-F200-4A59-988C-D260BB711AC0Q39443442-31C4A51F-0C76-444F-934D-214493FC7990Q39471681-E0D4B186-3C10-4B7D-9D0F-67DC9B94FD99Q39482776-0039B512-A2FD-40B8-8A3D-715313D79F85Q39500667-2BCA3B57-5F2B-4DCD-9D1D-FAB3F5225E30Q40852736-0C9A8C2F-33BB-471F-91F0-123BD1F72CE0Q40857948-69AB79FA-B7A0-4AED-B8BC-51E00720888FQ41626524-F48C8275-34B9-48C4-B4C8-BA98F51945A6Q42280369-F8D78FA9-9938-4F8F-A5D1-BC9238531F55Q42548851-FEF2E5F2-CB8B-4A9C-B897-08D78C0BB67FQ43050704-73E01EAC-2326-4521-896C-F0A15F6837F9Q43997713-BD358014-057F-41E9-8D50-6AD86F2B6008Q44073651-A34C182F-5254-4F2D-A91B-75444CD94847Q44570003-12565C84-4A88-4679-AB57-EA22806EA66AQ44946344-68D1427E-5011-46A3-9464-1CADA137D389Q46008523-FFE64E62-EBC4-4413-9C77-7335990A2D59Q46955158-85C987F0-4AAF-480E-A6DC-5FF8180A1624Q47965497-29F9B86F-99D3-4C94-A07C-5BB2E344B16BQ48089043-FF53C911-C4EC-45C6-A83D-1749148C7D70Q48715691-45EC4229-B257-4E58-A78C-24C4CF6AB184
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im September 1991 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 1991
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Oral sumatriptan in acute migraine
@en
Oral sumatriptan in acute migraine
@nl
type
label
Oral sumatriptan in acute migraine
@en
Oral sumatriptan in acute migraine
@nl
prefLabel
Oral sumatriptan in acute migraine
@en
Oral sumatriptan in acute migraine
@nl
P2093
P50
P1433
P1476
Oral sumatriptan in acute migraine
@en
P2093
G Symington
P F Bladin
P304
P356
10.1016/0140-6736(91)90666-D
P407
P577
1991-09-01T00:00:00Z